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10. At a Glance Commentary: 
Scientific Knowledge on the Subject 
Transfusion of stored red blood has been reported to increase pulmonary complications 
and the mortality rate of critically ill patients. During storage, red blood cells undergo 
progressive structural and functional changes reducing their oxygen transport capacity 
and viability, leading to hemolysis and releasing hemoglobin, heme and iron into 
circulating plasma. In experimental studies, plasma hemoglobin causes 
vasoconstriction, inflammation, and thrombosis. By elucidating the mechanisms of injury 
due to stored blood transfusion, novel therapies might be identified to prevent harm.  
What This Study Adds to the Field.  
This study demonstrates an increased pulmonary artery pressure following transfusion 
of one unit of 40 day stored autologous blood in overweight subjects with endothelial 
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 dysfunction, which is prevented by breathing nitric oxide. This study did not find any 
evidence of systemic hemodynamic changes or systemic inflammation after stored 
blood transfusion. 
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Abstract 
 
Rationale: Transfusion of erythrocytes stored for prolonged periods is associated with 
increased mortality. Erythrocytes undergo hemolysis during storage and after 
transfusion. Plasma hemoglobin scavenges endogenous nitric oxide leading to systemic 
and pulmonary vasoconstriction. 
Objectives: We hypothesized that transfusion of autologous blood stored for 40-days 
would increase the pulmonary artery pressure in volunteers with endothelial dysfunction 
(impaired endothelial production of nitric oxide). We also tested whether breathing nitric 
oxide before and during transfusion could prevent the increase of pulmonary artery 
pressure. 
Methods: Fourteen obese adults with endothelial dysfunction were enrolled in a 
randomized cross-over study of transfusing autologous, leukoreduced blood stored for 
either 3-days or 40-days. Volunteers were transfused with 3-day blood, 40-day blood, 
and 40-day blood while breathing 80 parts per million nitric oxide. 
Measurements and main result: The age of volunteers was 41±4 years (mean±SEM), 
and their Body Mass Index was 33.4±1.3 Kg/m2. Plasma hemoglobin concentrations 
increased after transfusion with 40-day and 40-day plus nitric oxide blood but not after 
transfusing 3-day blood. Mean pulmonary artery pressure, estimated by transthoracic 
echocardiography, increased after transfusing 40-day blood (18±2 to 23±2 mmHg, 
p<0.05) but did not change after transfusing 3-day blood (17±2 to 18±2 mmHg, p=0.5). 
Breathing nitric oxide decreased pulmonary artery pressure in volunteers transfused 
with 40-day blood (17±2 to 12±1 mmHg, p<0.05).  
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Conclusions: Transfusion of autologous leukoreduced blood stored for 40-days was 
associated with increased plasma hemoglobin levels and increased pulmonary artery 
pressure. Breathing nitric oxide prevents the increase of pulmonary artery pressure 
produced by transfusing stored blood. 
 
 
Abstract: 249 words 
Key words: Hemoglobins; Hypertension, pulmonary; Nitric oxide; Endothelium; 
Echocardiography 
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Introduction 
 
Blood transfusion is a common medical intervention, with more than fourteen million 
units of blood transfused annually in the USA (1). In developed countries, non-infectious 
hazards of transfusion, such as transfusion-related acute lung injury, have emerged as 
the leading complications of blood transfusion (2). In particular, the combination of 
transfusing red blood cells (RBC) stored for longer than 14-days and preexisting 
diseases such as diabetes and atherosclerosis in the recipient are associated with 
increased mortality (3-5). Conversely, other clinical studies have not reported adverse 
effects associated with transfusion of longer stored erythrocytes (6, 7). 
 
The US Food and Drug Administration allows RBCs to be stored for up to 42-days (1). 
During storage, RBCs undergo progressive structural and functional changes that 
reduce oxygen-transport capacity and viability, leading to hemolysis and the release of 
microparticles, hemoglobin, heme and iron into the circulation (8-10).  
 
Nitric oxide (NO) is a potent, endogenous dilator of vascular smooth muscle. Circulating 
hemoglobin, both free in plasma and contained in shed microparticles, avidly scavenges 
NO via the dioxygenation reaction, depleting vascular NO levels and resulting in 
vasoconstriction (11). Since pulmonary vasoconstriction was produced in animal models 
by stored RBC transfusion and prevented by breathing NO (12), we previously tested 
whether breathing low levels of NO could selectively dilate the pulmonary circulation 
without producing systemic vasodilation or hypotension (13).  
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In awake mice with endothelial dysfunction, characterized by reduced vascular NO 
availability, transfusing cell-free hemoglobin produces marked systemic vasoconstriction 
and hypertension (14). In a subsequent study, Yu et al. demonstrated that transfusing 
murine RBCs stored for 14-days induces systemic vasoconstriction and inflammation in 
diabetic mice with endothelial dysfunction and that breathing NO prevents the 
hypertension induced by transfusing stored RBCs (15). Breathing NO oxidizes plasma 
hemoglobin to methemoglobin, a form of hemoglobin that does not scavenge NO, 
blocking the vasoconstriction response (16). Hypertension and vasoconstriction were 
shown to be caused by transfusing the supernatant of stored murine RBCs, but 
transfusing washed 14-day stored RBCs did not cause vasoconstriction (15). In awake 
lambs, Baron et al. reported that autologous leukoreduced red blood cells stored for 40-
days induced pulmonary hypertension and inflammation, which was prevented by 
breathing NO (12, 17).  
 
In our previous study of healthy young volunteers (with intact endothelial function), 
transfusion of one unit of autologous, leukoreduced blood stored for 40-days neither 
changed systemic blood pressure nor impaired endothelial function, despite increasing 
plasma levels of cell-free hemoglobin. However, we did not assess pulmonary artery 
pressure (PAP) (10). In the present study, we selected overweight and obese 
volunteers with pre-existing systemic endothelial dysfunction to assess the systemic 
and pulmonary vascular response to transfusion with stored autologous blood. 
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We hypothesized that transfusion of stored blood would increase pulmonary and/or 
systemic vasoconstriction by presenting a load of NO-scavenging hemoglobin in the 
presence of pre-existing impaired endothelial function (18). We also tested the 
hypothesis that breathing NO, before and during transfusion, would prevent the 
vasoconstrictor effects of transfusing stored autologous blood. 
  
 
Materials and Methods 
 
Population and study protocol.  
The inclusion criteria to participate in this trial were: age over 18 and below 60 years; 
body mass index (BMI) between 27 and 45 kg/m2; evidence of impaired systemic 
endothelial function, as assessed by reduced post-ischemic vasodilation (natural log 
(Ln) of reactive hyperemia index (RHI), LnRHI≤0.75) (19). 
 
The study protocol was a three-arm cross-over study of autologous blood transfusion in 
volunteers with systemic endothelial dysfunction. Volunteers received in random order 
autologous leukoreduced blood stored between 2 and 3 days (3d challenge), 
autologous leukoreduced blood stored for 38 to 42 days (40d challenge), or autologous 
leukoreduced blood stored for 38 to 42 days while breathing NO (80 part per million 
(ppm)) (40d+NO challenge).  
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Venous blood was sampled before and 10 min, 1, 4 and 24h after completion of each 
blood transfusion to study plasma and serum biomarkers of hemolysis, inflammation, 
and organ injury.  
 
 
Echocardiography and hemodynamic measurements  
Transthoracic echocardiography (TTE) was performed before blood transfusion and 
again 15 minutes before the end of the blood transfusion (Supplemental Figure E1). In 
most of the volunteers, because a tricuspid regurgitation jet was not present for 
analysis, the pulmonary artery acceleration time (PAAT) was measured to estimate the 
mean pulmonary artery pressure (20, 21). PAAT was defined as the interval between 
the onset of systolic pulmonary arterial flow and the peak flow velocity. PAAT was also 
normalized by the right ventricular ejection time (RVET) (interval between the onset of 
RV ejection and the time of systolic pulmonary arterial flow cessation). To estimate 
mean PAP, we used a validated formula (21). All measurements were performed by the 
study cardiologist and reviewed by a second cardiologist, both of whom were blinded to 
the treatment. 
 
 
Statistical analysis  
We anticipated enrolling a total of 14 subjects in this crossover-randomized study (42 
blood challenges). Sample size calculation and statistical analyses were performed 
using STATA-12 software value as detailed in the online supplements. Continuous 
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variables are expressed as mean ± standard error of the mean (SEM) or median and 
interquartile range (IQR), as appropriate. Statistical significance was reached with p 
<0.05.  
 
Additional details on the study protocol, NO delivery, estimation of systolic and mean 
PAP and statistical methods can be found on the online-supplement. 
 
 
Results 
 
Fifty-seven volunteers were screened for a reduced RHI, and fourteen were enrolled in 
the study (9 males and 5 females). Twelve volunteers completed the study, and two left 
the study before finishing all three phases (Figure 1). Demographic characteristics are 
shown in Table 1. Endothelial dysfunction was present in all participants, as reflected by 
a low RHI at the time of screening (LnRHI=0.46±0.03) (18), and baseline (before 
transfusion). Estimated mean PAP at baseline was 18±1 mmHg, and systolic PAP was 
39±2 mmHg (Figure 2, Table 2).  
 
 
Pulmonary artery pressure is increased during transfusion of 40d stored blood, 
unchanged after 3d, and decreased during 40d+NO 
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Blood transfusion with 3d challenge showed no systemic or pulmonary hemodynamic 
changes except for a transient decrease in heart rate following transfusion (Table 2, 
Supplemental TableE1).  
 
Similarly, blood transfusion with 40d challenge did not change systemic blood pressure, 
cardiac output, or RHI and only transiently decreased heart rate following transfusion. 
However, during transfusion, we measured a decreased PAAT and PAAT/RVET 
(p=0.006 and p=0.004 respectively) corresponding to an increase of mean and systolic 
PAP of 5 and 6 mmHg, respectively (p=0.009 and p=0.006, respectively; Figure 2, 
Table 2, Supplemental Table E1). 
 
When volunteers breathed NO before and during transfusion of 40d stored blood 
(40d+NO challenge), the PAAT and PAAT/RVET increased (p=0.004 and p=0.009, 
respectively) and the mean-PAP decreased by 5 mmHg, and the systolic PAP 
decreased by 7 mmHg (p=0.005, and p=0.004, respectively), while systemic vascular 
hemodynamic measurements were unchanged (Figure 2, Table 2, Supplemental Table 
E1). 
 
When mean PAP values were compared, we found that during transfusion PAP tended 
to be greater in the 40d challenge group as compared to PAP in the 3d challenge group 
(40d vs. 3d, p=0.054); also, PAP was lower in the 40d+NO group compared to PAP in 
the 3d group (40d+NO vs. 3d, p=0.007); and, the PAP was markedly greater in the 40d 
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challenge group as compared to PAP in 40d+NO (40d vs. 40d+NO, p=0.001; Figure 2, 
Table 2). 
 
 
Transfusion of blood stored for 40-days is associated with an increased plasma 
hemoglobin level, and plasma NO consumption is increased only after 
transfusing 40d stored blood 
Transfusion with 3d challenge did not change the levels of plasma hemoglobin, plasma 
NO consumption (Figure 3), serum levels of iron and indirect bilirubin (Supplemental 
Figure E3), indicating the absence of hemolysis.  
 
Plasma hemoglobin levels almost doubled between 1h and 4h after transfusion with 40d 
challenge (plasma hemoglobin at 4h differs from plasma hemoglobin before transfusion, 
p=0.001; Figure 3A, 3B). Plasma NO consumption increased at 4h after transfusion 
(p<0.001, Figure 3B). Hemolysis associated with transfusion of 40d challenge was 
confirmed by increased serum levels of iron and indirect bilirubin, which peaked at 4h 
(Supplemental Figures E3A, E3B).  
 
After transfusion with 40d+NO challenge, plasma hemoglobin levels increased between 
1h and 4h (at 4h after initiation of transfusion vs. before transfusion, p<0.001). Serum 
iron levels, and indirect bilirubin increased similarly between 1h and 4h (Figure 3A, 
Supplemental Figures E3A, and E3B). However, in volunteers breathing NO, there was 
no increase in plasma NO consumption (Figure 3B). 
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Since breathing NO oxidizes plasma hemoglobin to methemoglobin, thereby, reducing 
the scavenging of NO, we measured the values of plasma NO consumption in the 3d 
and 40d transfusion challenges and correlated them with circulating levels of plasma 
hemoglobin (p<0.001, correlation between log10 plasma hemoglobin levels vs. log10 
plasma NO consumption, Figure 3C). Moreover, plasma NO consumption at 10 min 
after transfusion in the 3d and 40d challenge groups was associated with the change 
(∆) in mean PAP during blood transfusion from baseline (p<0.001, correlation between 
log10 plasma NO consumption levels at 10 min vs. ∆ mean PAP, Figure 3D).  
As expected, in the 40d+NO challenge, there was no correlation between plasma NO 
consumption and plasma hemoglobin levels or between plasma NO consumption at 10 
min and PAP (data not shown). 
 
 
Supernatant levels of hemoglobin in the PRBC units is increased with storage 
time and correlates closely with supernatant NO consumption  
Supernatant hemoglobin and NO consumption levels in the RBC units of the 40d and 
40d+NO challenges were approximately four times higher than those in the 3d RBC 
units (Figures 4A, 4B). NO consumption in the supernatant of the RBCs units of the 3d, 
40d, and 40+NO challenges closely correlated with supernatant levels of hemoglobin 
(p<0.001, correlation between log10 supernatant hemoglobin vs. log10 supernatant NO 
consumption, Figure 4C). The ∆ mean PAP in the 3d and 40d challenge groups 
correlated with the levels of NO consumption in the supernatant of the transfused RBC 
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unit (p=0.003, correlation of the log supernatant NO consumption vs. ∆ mean PAP, 
Figure 4D). In the 40d+NO challenge group the ∆ mean PAP did not correlate with the 
level of NO consumption in the supernatant of the transfused RBC units. 
 
 
Endothelial dysfunction is associated with low plasma levels of NO metabolites at 
baseline and NO metabolites remain low after transfusion of 40d stored blood. 
Breathing NO immediately increases plasma nitrate levels but not plasma nitrite 
levels 
At baseline (before transfusion), endothelial dysfunction in our overweight-obese 
volunteers was characterized by a reduced RHI (decreased availability of endothelial 
NO) (22) and confirmed by extremely low plasma levels of nitrite and nitroso 
compounds compared to prior reports in the literature (Supplemental Table E3) (10, 23, 
24). Other NO metabolites were comparable to the levels that we previously reported in 
young healthy human volunteers (Supplemental Table E3) (10).  
 
Levels of NO metabolites in plasma and erythrocytes showed similar trends after 
transfusion with 3d and 40d challenges (Supplemental-Figure E4). There was no 
significant decrease in plasma and erythrocyte nitrate levels after transfusion with 3d 
and 40d challenges. Plasma nitrite levels increased slightly, while erythrocyte nitrite 
levels halved immediately following transfusion, and there was no change in the plasma 
or erythrocyte levels of nitroso compounds after transfusion with either 3d or 40d stored 
RBCs. 
Page 19 of 72  AJRCCM Articles in Press. Published on 27-August-2014 as 10.1164/rccm.201405-0850OC 
 Copyright © 2014 by the American Thoracic Society 
10
 
 
After transfusion with 40d+NO stored blood, nitrate levels in plasma and erythrocytes 
increased immediately after inhalation of NO and returned to baseline levels at 24h 
(Supplemental Figures E4A, E4D). Plasma levels of nitrite increased only after 24h in 
the 40d+NO challenge group (Supplemental FigureE4). Concentrations of other nitric 
oxide metabolites (RXNO, NOx) in plasma and erythrocytes after NO breathing did not 
significantly differ from the values after 3d or 40d transfusions (without NO breathing). 
 
 
Discussion  
We investigated the effects of transfusing stored autologous RBCs on systemic and 
pulmonary hemodynamics and systemic endothelial function in obese adult volunteers 
with endothelial dysfunction. The principal finding of our study was that auto-transfusion 
of one unit of leukoreduced blood stored for 40d increased the pulmonary artery 
pressure, as estimated by transthoracic echocardiography. Inhalation of 80 ppm NO 
prevented the increase in pulmonary artery pressure induced by transfusing 40d stored 
blood. A second important finding was the absence of systemic hypertension, 
inflammation, or organ injury after transfusion of 40d stored blood in our volunteers with 
pre-existing systemic endothelial dysfunction. We previously reported that diabetic mice 
with endothelial dysfunction were sensitized to systemic vasoconstriction after the 
transfusion of stored syngeneic blood (15). We also noted that both diabetic and high fat 
diet-fed mice developed an enhanced systemic inflammatory response after stored 
blood transfusion (15, 25). Thus, we were surprised that our obese volunteers with a 
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markedly reduced RHI did not show any systemic vasoconstriction or inflammation after 
stored 40d blood transfusion. Similar findings of an absence of inflammation has been 
reported after transfusion of stored blood into healthy (non-obese) volunteers (10, 26) 
and ICU patients (27).  
 
We measured the pulmonary artery acceleration time (PAAT) by transthoracic 
echocardiography and calculated an estimated mean and systolic PAP (20, 21). Our 
volunteers with endothelial dysfunction exhibited an increased PAP at baseline (before 
transfusion). These observations are in agreement with those of McQuillan et al. (27), 
who reported that patients with a higher BMI had an increased systolic PAP. It is 
possible that the combination of obesity and systemic endothelial dysfunction placed 
our volunteers at higher risk for pulmonary vasoconstriction when challenged with a 
stored blood transfusion. Since transfusion with blood stored for 40d did not change the 
cardiac output, the increase of PAP that we measured is most likely explained by an 
increase of pulmonary vascular resistance due to pulmonary vasoconstriction. Without 
inserting a pulmonary artery catheter, we are unable to determine whether transfusion 
altered the pulmonary capillary wedge pressure. However, as no change in PAP was 
measured following transfusion with blood stored for 3d, it is unlikely that the wedge 
pressure was changed by transfusing one unit of 40d RBCs.  
 
Transfusion of blood stored for prolonged periods into either lambs or dogs produces 
acute pulmonary hypertension (12, 28-30). Baron et al. developed a model of 
autologous blood transfusion in the awake lamb and reported that top-load transfusion 
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of one unit of blood stored for 40 days induced transient pulmonary vasoconstriction 
and an increased pulmonary artery pressure (12). Treating lambs with a low dose of L-
NAME to mimic endothelial dysfunction markedly augmented the pulmonary 
vasoconstriction following transfusion with stored blood (12). In a subsequent study of 
lambs resuscitated with autologous stored blood after hemorrhagic shock, Baron and 
colleagues reported enhanced pulmonary vasoconstriction and hypertension (17). 
Moreover, Solomon et al. described persistent pulmonary hypertension in a septic 
canine model subjected to an exchange transfusion with stored canine donor blood 
(28). In elegant studies, Stevens et al. showed that the relevant hydrostatic pressure for 
alveolar edema formation is the transcapillary pressure, which depending on the model 
may or may not correlate with PAP (31, 32). In Solomon’s canine study, the increase of 
pulmonary hypertension after stored blood transfusion was associated with more severe 
lung damage than the fresh blood transfused control, evidenced by increased necrosis, 
hemorrhage, and thrombosis (28). Similarly, Baron et al. reported that two of six animals 
transfused with stored blood developed severe pulmonary edema (17). Thus, any 
connection between the increased pulmonary artery pressure and lung edema, 
necrosis, hemorrhage and thrombosis especially in patients with acute lung injury 
receiving stored blood should be closely examined. 
 
To determine the degree of depletion of NO in plasma after blood transfusion and the 
benefits of breathing NO, we measured NO consumption in both stored RBC 
supernatant and the recipient’s plasma after transfusion. During storage, we found that 
the NO consumption of the supernatant was markedly increased, as others have 
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reported (9, 17). Supernatant NO consumption closely correlated with the level of 
plasma hemoglobin in the supernatant. The increase of PAP during transfusion 
correlated with both the level of NO consumption of the supernatant in the transfused 
RBC unit and with the level of NO consumption in the transfusion recipient’s plasma 
measured 10 min after completing the transfusion. It is likely that the increase of PAP 
during transfusion of blood stored for 40 days is due to both the transfusion of 
hemoglobin contained in the blood storage unit and to hemolysis of circulating 
transfused erythrocytes. The peak level of plasma hemoglobin in our volunteers 
occurred between 1 to 4 hours after the transfusion, consistent with ongoing hemolysis 
after transfusion.  
 
Breathing NO is an efficacious and safe method to selectively reduce pulmonary 
hypertension. Minneci et al demonstrated that inhaled NO reversed the pulmonary 
hypertension produced by hemoglobin infusion in dogs (16). Many thousands of 
patients with acute pulmonary hypertension have been successfully treated with inhaled 
NO (13, 33). In children with pulmonary endothelial dysfunction proven by a lack of 
response to acetylcholine infusion, and pulmonary hypertension following 
extracorporeal bypass, Wessel et al. showed that PAP was normalized by breathing NO 
(34). In our study, breathing NO before and during transfusion abolished the acute 
pulmonary pressure increase induced by transfusing blood stored for 40d in volunteers 
with endothelial dysfunction. Thus, we believe that inhaled NO prevented or reversed 
any vasoconstriction due to NO scavenging by hemoglobin. We reviewed other possible 
sources for the increase of PAP with stored blood transfusion such as reduced red cell 
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deformability (35), and presumably increased viscosity. There is limited evidence that 
NO exposure can reduce red cell deformity (36). If reactive oxygen species are elevated 
by iron released by stored blood and help produce vasoconstriction, it is possible that 
inhaled NO could scavenge oxygen free radicals (37). These results suggest that 
patients with endothelial dysfunction that receive stored blood transfusions could be 
treated with inhaled NO to prevent an increased pulmonary pressure.  
 
Finally, to further investigate the response to inhaled NO after transfusion of stored 
blood in volunteers with endothelial dysfunction, we measured NO metabolites in 
plasma and erythrocytes. We report that baseline levels of nitrite were three times lower 
than the levels we measured in healthy young volunteers without endothelial 
dysfunction (10). Unlike our previous study in healthy volunteers, volunteers with 
endothelial dysfunction showed no change of NO metabolite levels after transfusion of 
either 3d or 40d stored blood challenges. In particular, plasma nitrite levels, despite a 
slight increase immediately after transfusion of 3d or 40d blood, remained at extremely 
low levels when compared to healthy individuals. It is likely that the diseased 
endothelium of our obese volunteers was incapable of increasing NO synthesis after 
transfusing free hemoglobin. This is in contrast to our previous study of healthy 
volunteers where circulating nitrite levels were increased after stored blood transfusion.  
Breathing NO produced an immediate increase of erythrocytic and plasma levels of 
nitrate but not nitrite. Thus, it is unlikely that breathing NO produced its effects via nitrite 
release.  
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Our study has several limitations. First, this is an exploratory study conducted with only 
14 human volunteers. Larger clinical trials of stored blood transfusion may eventually 
clarify whether an increase in pulmonary artery pressure manifests after multiple 
transfusions with stored blood and if this translates to increased adverse pulmonary and 
cardiac events. Second, we did not explore the effects of breathing NO in the absence 
of a transfusion in overweight volunteers with systemic endothelial dysfunction; we also 
did not study the effects of a volume challenge (saline or albumin) on 
systemic/pulmonary hemodynamics; and lastly we did not investigate the effects of 
breathing NO during transfusion of 3d stored blood. These additional control groups 
would need to be examined in future studies. Third, without continuous monitoring of 
pulmonary artery pressure by a pulmonary catheter, we do not know if the peak of in-
vivo hemolysis at 1-4 hours correlates with an increased PAP. Future studies should 
investigate whether in-vivo hemolysis causes persistent pulmonary vasoconstriction. 
Lastly, we did not evaluate other possible noxious effects of stored blood transfusion, 
such as: iron and heme toxicity, micro-particles, protein oxidation, or lipid peroxidation 
of the RBC membrane. 
 
In conclusion, in our randomized crossover trial of autologous leukoreduced stored 
blood transfusion in overweight and obese adult volunteers with systemic endothelial 
dysfunction, we found that transfusion of leukoreduced erythrocytes stored for 40 days 
was associated with an increased pulmonary artery pressure, most likely due to NO 
depletion by plasma hemoglobin. Selective pulmonary vasodilation induced by 
breathing 80 ppm NO prevented the increase of PAP after the transfusion of 40-day 
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stored red cells. This study demonstrates an increase in PAP following transfusion of 
40d stored blood and provides a safe and practical pharmacological intervention to 
avoid the increase of pulmonary artery pressure. Clinical trials of stored blood 
transfusion should prospectively search for pulmonary hypertension and any adverse 
effect of augmenting pulmonary edema, especially in critically ill patients with 
endothelial dysfunction and acute lung injury. 
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Figure 1. Study screening, enrollment and blood challenges. LnRHI: Natural 
logarithm of RHI 
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Figure 2. Breathing 80 ppm NO prevents transfusion related increase of PAP. (A) 
Transfusion of 40d stored blood decreased PAAT (p=0.006, 40d PAAT pre-transfusion 
vs. PAAT during-transfusion), while transfusion 40d+NO stored blood increased PAAT 
(p=0.004). (B) Mean PAP increased during 40d challenge (p=0.009); and decreased 
during 40d+NO challenge (p=0.005). Data presented as mean±SEM. *p<0.01, paired t-
test pre- vs during-transfusion measurements. 
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Figure 3. Plasma levels of hemoglobin, plasma NO consumption, and changes of 
mean PAP. (A) Plasma hemoglobin increased after 40d transfusion challenge (*p<0.01 
plasma hemoglobin at 1h and 4h measurements compared to baseline [=before 
transfusion]), and after 40d+NO challenge (#p<0.01 plasma hemoglobin at 10min, 1h, 
4h, 24h measurements compared to baseline in 40d challenge). No significant changes 
were found after challenge with 3d transfusion. (B) Plasma NO consumption increased 
only at 4h after transfusion of 40d stored blood (*p=0.001). (C) Plasma hemoglobin 
concentration at baseline, 10 min and 4 hours after transfusion in volunteers receiving 
3d and 40d challenges correlates with NO consumption (p<0.001) (D) Plasma NO 
consumption at 10 minutes after 3d and 40d challenges correlates with ∆ mean PAP 
(mmHg) (p<0.001). Data are presented as mean±SEM. In (A) and (B) a two-way 
ANOVA for repeated measures with post-hoc Bonferroni correction. In (C) and (D) 
measurements of plasma hemoglobin and NO consumption were transformed into a 
logarithmic10 scale. 
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Figure 4. Plasma hemoglobin and plasma NO consumption in the supernatant of 
RBC unit, and changes of mean PAP. (A) Supernatant hemoglobin levels contained in 
the 40d and 40d+NO stored blood units are higher than those in the supernatant of the 
3d stored units (# and * p<0.01). (B) Supernatant NO consumption is higher in the 40d 
and 40d+NO stored units as compared to the NO consumption of the 3d stored units (# 
and * p<0.01). (C) Supernatant NO consumption correlates with supernatant 
hemoglobin levels from all RBC units (p<0.001). (D) Supernatant NO consumption 
correlates with change of mean PAP after 3d and 40d challenges (p=0.003). Despite 
high NO consumption levels of the supernatant of the 40d+NO stored units, breathing 
NO decreases mean PAP. Data presented as median and IQR. In figure (A) and (B) the 
p value was calculated with a Kruskal-Wallis rank test. In figure (C) and (D) 
measurements of hemoglobin in the supernatant and NO consumption were 
transformed to a logarithmic10 scale. Note that there are 3 fewer points in Figure 4D 
compared to 3D: two samples from the 3-day stored blood units and one sample from 
the 40d stored unit were not obtained. 
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Table 1.  Baseline characteristics 
 
 
Data are shown as mean±SEM or count (%) 
Characteristics n=14 
Male, n (%) 9 (64%) 
Age, years 41±4 
Race, n (%)  
Caucasian 12 (86%) 
African-American 1 (7%) 
Asian 1 (7%) 
Hispanic 0 
ABO blood group, n 
(%) 
 
A 3 (22%) 
B 2 (14%) 
AB 2 (14%) 
0 7 (50%) 
BMI, kg/m2 33.4±1.3 
LnRHI 0.46±0.03 
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Table 2. Hemodynamic and transthoracic echocardiography (TTE) variables before 
(pre) and during transfusion.  
 
Data are shown as mean±SEM; *p<0.01 paired t-test values pre- vs during-transfusion. 
 
 3d (n=9)  40d (n=11)  40d+NO (n=12) 
pre during  pre during  pre during 
PAAT, ms 132±9 129±8  127±8 110±6*  132±7 154±7* 
PAAT/RVET 0.40±0.03 0.39±0.02  0.40±0.03 0.32±0.02*  0.39±0.02 0.46±0.02* 
mean-PAP, 
mmHg 
17±2 18±2  18±2 23±2*  17±2 12±1* 
systolic-
PAP, mmHg 
38±3 39±3  40±3 46±3*  38±3 31±2* 
CO, l/min 5.3±0.4 5.0±0.3  4.5±0.4 4.6±0.3  4.5±0.3 4.4±0.2 
LVEF, % 65±1 68±2  63±1 63±1  64±2 65±1 
SV, ml 87±8 82±7  77±8 78±8  75±6 76±5 
LnRHI 0.74±0.09 0.87±0.06  0.74±0.07 0.90±0.06  0.67±0.07 0.78±0.06 
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Online METHODS data supplement 
 
Institutional Review Board, Clinical trial registry (ClinicalTrial.gov) and 
Consolidated Standards of Reporting Trials (CONSORT), Independent Data 
Access and Analysis 
The Partners Institutional Review Board approved all procedures, and the enrolled 
subjects provided written informed consent. Volunteers were managed in the outpatient 
clinic of the Massachusetts General Hospital Blood Transfusion Service. The study was 
registered at clinicaltrials.gov and was assigned identifier number, NCT01529502.  
The trial follows the criteria listed by the Consolidated Standards of Reporting Trials 
(CONSORT) in all its parts (enrollment, intervention allocation, follow-up, data analysis, 
number of subjects). 
Two statisticians from Massachusetts General Hospital (Hui Zheng, PhD, Biostatistics 
Center, Massachusetts General Hospital, and Rajeev Malhotra, M.D., Cardiology 
Division, Department of Medicine) had full access to the primary data and performed 
analysts for the investigators. We thank them in acknowledgments. 
 
Blood bank processing 
Blood collection, testing, and transfusion were performed according to current clinical 
MGH procedures, which meet all requirements of the AABB and FDA.1 
 
Population, recruitment, inclusion and exclusion criteria 
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This study was conducted at the Massachusetts General Hospital in Boston from 
February 2012 to January 2014. From February 6, 2012 to June 30, 2012 we recruited 
volunteers via the MGH Weight Center and the Partners clinical studies website.  
 
Volunteer recruitment 
We recruited volunteers through the MGH-Weight Center and the Partners clinical 
studies website.  Our inclusion criteria were: age over 18 and below 60 years; body 
mass index (BMI) between 27 and 45 kg/m2; evidence of impaired systemic endothelial 
function, as assessed by reduced post-ischemic vasodilation (natural log (Ln) of 
reactive hyperemia index (RHI), LnRHI≤0.75)19; an otherwise normal physical exam; 
and laboratory tests within normal limits.  
 
Inclusion criteria were: age over 18 and below 60 years; body mass index (BMI) 27 to 
45 kg/m2; evidence of impaired systemic endothelial function assessed by a significantly 
reduced post-ischemic vasodilation (LnRHI≤0.75), with an otherwise normal physical 
exam and normal blood levels of white blood cells and platelets, hemoglobin, 
electrolytes, urea, creatinine, glucose, and transaminase.   
 
Exclusion criteria were: psychiatric disturbances, systemic disease with or functional 
limitations, active smoking or less than 1 year of smoking cessation, excessive alcohol 
use, taking any medications during the past 7 days, having received or donated blood in 
the last 4 months, any type of cancer or enrollment in another research study. 
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Study protocol 
The study protocol was a three-arm cross-over study of autologous blood transfusion in 
14 volunteers with systemic endothelial dysfunction. We transfused autologous 
leukoreduced RBCs to eliminate confounding immune factors. 
Volunteers fasted and drank only water for 8 hours or more prior to each transfusion. 
Volunteers received in random order autologous leukoreduced blood stored between 2 
and 3 days (3d challenge), autologous leukoreduced blood stored for 38 to 42 days 
(40d challenge), or autologous leukoreduced blood stored for 38 to 42 days while 
breathing NO (80 ppm) (40d+NO challenge). Each subject waited for 2 weeks between 
each phase of the study. The order of the three study challenges was randomized 
according to a block randomization protocol with an allocation ratio of 1:1:1 for 
assigning subjects to each study arm. After blood transfusion, volunteers rested about 4 
hours to allow monitoring and blood sampling. 
During the 3d challenge phase of the study, volunteers donated a unit of blood, which 
was leukoreduced and stored in AS-1, and then transfused IV over 45 minutes into the 
same subject after 3-days of storage at 4°C in the MGH Blood Bank. In the 40d 
challenge phase, one unit of blood was obtained from the same volunteers, stored as 
described above, and autotransfused 40-days later. In the 40d+NO challenge group, the 
volunteers were autotransfused with blood stored for 40-days and breathed NO 
(80ppm) by mask for an hour before and during the 45 minutes of autologous blood 
infusion (total NO administration time was 105 minutes).  
Venous blood was sampled before and 10 min, 1h, 4h and 24h after completion of each 
blood transfusion (Supplemental Figure E1). 
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 Assessment of endothelial function 
Endothelial function was assessed by a non-invasive measurement of peripheral 
vasodilator response (reactive hyperemia index, RHI).2,3   
- Reactive hyperemia index: We measured the RHI to assess digital vasodilatory 
capacity after 5 minutes of transitory arm ischemia.  Subjects were supine in a 
quiet, temperature-controlled room. Inflatable probes were placed on the index 
finger of each hand. Pulse volume amplitude was measured using the EndoPAT 
2000 instrument (Itamar Medical Ltd., Caesarea, Israel). After 5 minutes of PAT 
recording (pre-ischemia phase), the brachial blood pressure cuff was inflated for 
5 minutes (ischemic phase) to a pressure of 250 mmHg producing transitory 
ischemia of one arm (verified by absence of PAT signal).  The cuff was then 
released (post-ischemia phase), and the PAT signal recorded for another 5 
minutes. The PAT ratio (post-ischemia to pre-ischemia PAT amplitude) was 
calculated for each 30-second interval of the post-ischemia phase in the test 
finger and then divided by the ratio of the control finger to account for any 
systemic hemodynamic changes.  RHI was defined as the mean PAT ratio during 
the 5 minutes of hyperemia after cuff release. RHI was assessed before 
transfusion and again at 10 minutes, 1 hour, and 4 hours after the end of the 
transfusion. PAT is shown as a natural logarithm transformation as described by 
the Framingham study group.2,3 Hamburg et al. showed that in a healthy 
population free from cardiovascular risk factors and with normal endothelial 
function the mean LnRHI is 0.76±0.36.3 We, therefore, decided to include 
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volunteers with a body mass index (BMI) from 27 to 45 kg/m2 and a screening 
value of LnRHI ≤ 0.75. The mean of the LnRHI of the 14 volunteers that entered 
this study was 0.46±0.03 (mean±SEM). 
 
Inhaled Nitric Oxide delivery 
Nitric oxide was delivered at 80 ppm using the Ikaria INOvent Delivery System (Ikaria, 
Hampton, NJ). The system was calibrated and purged according to the manufacturer’s 
recommendations (INOvent Delivery System Operation and Maintenance Manual. 
Datex-Ohmeda 2000) prior to each use and the spontaneous breathing circuit was 
similar to that described by the manufacturer (INOvent Delivery System Operation and 
Maintenance Manual. Datex-Ohmeda 2000).4 A room air concentrator was set to deliver 
40 Liters/minute providing the bulk of the inspiratory gas flow into the circuit and 
reservoir bag (Supplemental figure E5). Additionally, 1 Liter/minute of oxygen was 
added with a 15 x 22mm side arm adaptor to maintain an inspired oxygen concentration 
of 21 to 23%. Inspired nitric oxide, nitrogen dioxide, and oxygen concentrations as well 
as the volunteer’s SpO2 were continuously monitored throughout the procedure.  
 
Echocardiography and hemodynamics 
Transthoracic echocardiography (TTE) was performed before blood transfusion and 
again 15min before the end of the blood transfusion (Supplemental figure E1). We used  
an echocardiographic system (iE33, Philips Medical Systems, Andover, MA; Vivid 7, GE 
Healthcare, Milwaukee, WI), according to the technical guidelines of the American 
Society of Echocardiography.5 In most of the volunteers, because a tricuspid 
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regurgitation jet was not present for analysis, the pulmonary artery acceleration time 
(PAAT) was measured to estimate the mean pulmonary arterial pressure (PAP).6,7 
PAAT was defined as the interval between the onset of systolic pulmonary arterial flow 
and the peak flow velocity. PAAT was also normalized by the right ventricular ejection 
time (RVET) (interval between the onset of RV ejection and the time of systolic 
pulmonary arterial flow cessation). 
 
To estimate mean pulmonary arterial pressure (PAP), we used a formula validated by 
others comparing PAAT with direct clinical measurements of mean PAP with a 
pulmonary arterial catheter.7 
Log10 (estimated mean PAP) = - 0.0068 (PAAT) + 2.1 
 
 
To estimate systolic PAP, we used a formula that was validated by comparing PAAT 
with direct clinical measurements of systolic PAP with pulmonary arterial catheters.6  
 
Log10 (estimated systolic PAP) = - 0.004 (PAAT) + 2.1 
 
 
Stroke volume was calculated as the cross-sectional area of the LV outflow tract (LVOT) 
multiplied by the velocity time integral of the LVOT (VTILVOT). The cross-sectional area 
of the LVOT was derived from its diameter measured in the parasternal long axis view, 
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and calculated as P(diameter LVOT)2/4. Cardiac output (CO) was calculated as the 
product of SV and heart rate.  
 
All values used for analysis of each patient represent the average of three consecutive 
cardiac cycles. All measurements were performed by the study cardiologist and 
reviewed by a second cardiologist, both were blinded to the study phase. 
 
Blood pressure and heart rate were recorded with a Propaq non-invasive monitor 
(Welch Allyn Inc. Skaneateles Falls, NY) at 15 min intervals before and during 
transfusion, and for 4h following completion of the transfusion. 
 
Blood samples 
Before transfusion a large-bore intravenous catheter was placed in an antecubital vein 
for blood withdrawal. Before transfusion, and at 10min, 1h, 2h, 4h and 24h after 
transfusion we measured a comprehensive metabolic panel, complete blood count with 
differential, plasma cytokines, serum iron levels, plasma cell-free hemoglobin, LDH, 
haptoglobin, hemopexin, NGAL, concentration of cell-free hemoglobin, as well as NO 
metabolites (nitrite, nitrate, RNNO and RSNO) in both plasma and erythrocytes. Plasma 
NO consumption was measured before blood transfusion and at 10 minutes and 4 
hours after transfusion. 
Additionally, an aliquot of blood from each red cell unit was collected at the end of the 
assigned storage period to measure cell-free hemoglobin, NO supernatant consumption 
and NO metabolite concentrations. 
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Routine tests such as a comprehensive metabolic panel, serum iron, LDH and white 
blood cell concentration (WBC) were performed at the MGH clinical-laboratory. 
Additional measurements are detailed below: 
- Haptoglobin measurement: Haptoglobin concentration was measured with a 
haptoglobin ELISA kit (GenWay Biotech, Inc., San Diego, CA) after plasma de-
complementation by incubation at 5-6° C for 30 minutes. 
- Neutrophil gelatinase-associated lipocalin (NGAL) measurement: Plasma 
NGAL levels were determined with a NGAL ELISA kit (Alpco Immunoassays, 
Salem, NH). 
- Plasma hemoglobin measurement: Plasma hemoglobin was measured with a 
QuantiChrom Hemoglobin Assay Kit (BioAssaySystems, Hayward, California). 
These samples were collected using a 16 or 18G catheter in a vein and avoiding 
negative aspirating pressures to minimize ex vivo hemolysis. Grossly hemolyzed 
samples were excluded (5 out of a total of 230 samples).  
- Nitric Oxide (NO) consumption: Plasma NO consumption was determined with 
a NO chemiluminescence analyzer (Sievers 280i, GE, Boulder, CO) as described 
previously.8  
- NO metabolite measurements: After collection, samples were immediately 
centrifuged at 2500 rpm for 10 minutes at 4 °C and separated into aliquots of 
plasma and red blood cell lysates, snap frozen, then stored at -80 °C until further 
analyses. Quantification of nitrosation products (protein S-nitrosothiols (RSNO) 
and N-nitrosamines (RNNO)) was achieved by group-specific denitrosation after 
injection of one set of samples into a triiodide-containing reaction mixture 
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continuously purged with nitrogen gas and quantification of evolved NO was 
performed using a gas phase chemiluminescence detector (CLD 77am sp, 
EcoPhysics, Ann Arbor, MI). Discrimination between RSNO and RNNO products 
was achieved by pre-treatment of sample aliquots with mercuric chloride (HgCl2).  
The effect of nitrite was excluded by pre-incubation of samples with acidic 
sulfanilamide.  Oxidation products of nitric oxide (nitrate and nitrite) were 
quantified by ion chromatography (ENO20 Analyzer, Eicom, San Diego, CA) 
using an aliquot of samples devoid of protein via precipitation with methanol.  
With red blood cell lysate an additional NO metabolite was taken into account; 
simultaneous determination of evolved NO using gas phase chemiluminescene 
from nitrosylated heme-products (NO-heme) was accomplished by injecting 
native untreated samples into solutions of potassium ferricyanide (K3[Fe(CN)6]). 
- Plasma cytokine measurement: Plasma cytokines [interleukin (IL)-1β, IL-
12p70, IFN-gamma, IL-6, IL-8, IL-10, TNF-α] were measured using a multiplex, 
electrochemiluminescence assay [Meso Scale Diagnostics, Rockville, MD]. The 
limit of detection was 0.2 pg/mL for IL-6; 0.3 pg/mL for  IL-12p70; 0.5 pg/mL for 
IFN-gamma and IL-1β; and 0.6 pg/mL for IL-8, IL-10, and TNF-α. 
- Plasma monocyte chemoattractant protein (MCP)-1: MCP-1 levels were 
quantified using ELISA kits (Quantikine ELISA, R&D Systems, Minneapolis, MN) 
following the manufacturer’s instructions.  
 
Statistical analysis 
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Although it is not possible to accurately predict the magnitude of the effects of 
transfusion on systemic endothelial function, we performed a power analysis and 
sample size calculation based on an estimate of a further reduction of RHI in volunteers 
with impaired endothelial function (LnRHI≤0.75) at the screening-visit due to their 
underlying overweight condition. 
We estimated enrolling a total of 14 subjects (42 blood challenges) in a crossover-
randomized study. Assuming a standard deviation of the differences between the two 
treatments within the same patient of 0.11, a sample size of 11 volunteers (33 blood 
challenges) will ensure 90% statistical power to detect a mean difference of 0.10 in 
LnRHI between the two treatments (2-sided paired t-test of the changes and 5% 
significance level). We decided to include a total of 14 volunteers (20% more than the 
calculated sample size) to account for unexpected dropouts from the study.  
Continuous variables are expressed as mean ± standard error of the mean (SEM) or 
median and interquartile range (IQR), as appropriate. Normal distribution was assessed 
using a Shapiro-Wilk test on baseline values (before transfusion values). A one-way 
analysis of variance (ANOVA) for repeated measures was used to test differences in 
baseline values of normally distributed variables among the three blood challenges. The 
effect of storage time of the RBC unit on hemodynamic variables after transfusion, as 
compared to pre-transfusion values, was assessed by a paired t-test. A Kruskal-Wallis 
rank test with post-hoc Bonferroni correction was applied to compare the levels of 
supernatant cell-free hemoglobin and supernatant NO consumption in the RBC units. A 
two-way ANOVA for repeated measures with crossover effect was used to detect 
overall differences among blood challenges along the follow-up time course. Variable 
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changes at each time point compared to baseline or compared to the other challenges 
were tested using post-hoc Bonferroni corrections for multiple comparisons. Regression 
analysis was performed using a generalized estimating equation (GEE) method 
accounting for within-patient repeated measurements. Statistical significance was 
reached when p-value <0.05. Statistical analyses were performed using STATA 12 
software (StataCorp LP, College Station, TX, USA) and GraphPad Prism 6 (GraphPad 
Software, San Diego, CA, USA).  
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Online RESULTS data supplement 
 
Fifty-seven volunteers were screened for a reduced RHI, and fourteen were enrolled in 
the study (9 males and 5 females). Twelve volunteers completed the study, and two left 
the study before finishing all three phases. One of the two who left the study, completed 
the 3d and 40d challenges and missed the 40d+NO challenge, and the second received 
only the 3d challenge (Figure 1). Echocardiographic measurements were not performed 
for the first transfusion challenge in four subjects. Data from these transfusion 
challenges were not included in subsequent analyses.  After completing the three 
transfusion challenges, the first four subjects returned to repeat the first transfusion 
challenge with the echocardiographic measurements described below. Demographic 
characteristics of the study group are shown in Table 1. Endothelial dysfunction was 
present in all participants, as reflected by a low RHI at the time of screening 
(LnRHI=0.46±0.03).  
 
At baseline (before transfusion), circulating total hemoglobin was 0.7 g/dl less in the 3d 
transfusion challenge group than in the 40d and 40d+NO groups, due to the recent 
blood donation in the 3d challenge group (Supplemental-Figure E2). There were no 
differences in other pre-transfusion laboratory values or hemodynamic parameters 
(Supplemental-Tables E1, E2, and E3). Baseline estimated mean PAP was 18±1 
mmHg, and systolic PAP was 39±2 mmHg (Figure 2 and Table 2).  
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No major adverse events occurred during or following autologous blood transfusion, or 
during or following inhalation of 80 ppm NO by mask. Blood levels of methemoglobin 
were <1.5% before, during, and after discontinuation of NO breathing. 
 
At baseline (before transfusion), circulating total hemoglobin was 0.7 g/dl less in the 3d 
transfusion challenge group than in the 40d and 40d+NO groups, due to the recent 
blood donation in the 3d challenge group (Supplemental-Figure E2). There were no 
differences in other pre-transfusion laboratory values or hemodynamic parameters 
(Supplemental-Tables E1, E2, and E3). 
 
 
Transfusion with autologous blood does not increase plasma levels of 
inflammatory cytokines or renal and hepatic injury markers 
With the exception of a transient increase in white blood cell concentration after 40d 
blood transfusion at 4h (p=0.008), the leukocyte concentrations did not differ after 
transfusion of 3d, 40d, or 40d+NO (Supplemental-Figure E2). Plasma levels of 
interleukin (IL)-1β, IL-12, IFN-gamma, IL-6, IL-8, IL-10, TNF-α, and MCP-1 were 
unchanged after transfusion of 3d or 40d stored blood (with or without inhaled NO) (data 
not shown). There was no change of creatinine, BUN, NGAL, AST, or ALT after 
transfusion of 3d, 40d, or 40+NO stored blood, except for a transient increase of 
creatinine in the 40d+NO at 4h (p=0.002) (Supplemental-Table E2). 
 
  
Page 57 of 72  AJRCCM Articles in Press. Published on 27-August-2014 as 10.1164/rccm.201405-0850OC 
 Copyright © 2014 by the American Thoracic Society 
 
References 
1. Carson JL, Grossman BJ, Kleinman S, Tinmouth AT, Marques MB, Fung MK, 
Holcomb JB, Illoh O, Kaplan LJ, Katz LM, Rao SV, Roback JD, Shander A, Tobian 
AAR, Weinstein R, Swinton McLaughlin LG, Djulbegovic B, Clinical Transfusion 
Medicine Committee of the AABB. Red blood cell transfusion: a clinical practice 
guideline from the AABB*. Ann. Intern. Med. 2012;157:49–58.  
2. Hamburg NM, Keyes MJ, Larson MG, Vasan RS, Schnabel R, Pryde MM, Mitchell 
GF, Sheffy J, Vita JA, Benjamin EJ. Cross-Sectional Relations of Digital Vascular 
Function to Cardiovascular Risk Factors in the Framingham Heart Study. 
Circulation. 2008;117:2467–2474.  
3. Hamburg NM, Palmisano J, Larson MG, Sullivan LM, Lehman BT, Vasan RS, Levy 
D, Mitchell GF, Vita JA, Benjamin EJ. Relation of Brachial and Digital Measures of 
Vascular Function in the Community: The Framingham Heart Study. Hypertension. 
2011;57:390–396.  
4. Datex-Ohmeda. INOvent Delivery System Operation and Maintenance Manual 
[Internet]. www.ikaria.com. 2000 [cited 2014 Feb 3];Available from: 
http://www.ikaria.com/therapies/INOMAX.html 
5. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, 
Gutgesell H, Reichek N, D S, I S. Recommendations for quantitation of the left 
ventricle by two-dimensional echocardiography. American Society of 
Echocardiography Committee on Standards, Subcommittee on Quantitation of 
Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989;2:358–367.  
6. Yared K, Noseworthy P, Weyman AE, McCabe E, Picard MH, MD ALB. Pulmonary 
Artery Acceleration Time Provides anAccurate Estimate of Systolic Pulmonary 
Arterial Pressure during Transthoracic Echocardiography. Journal of the American 
Society of Echocardiography. 2011;24:687–692.  
7. Kitabatake A, Inoue M, Asao M, Masuyama T, Tanouchi J, Morita T, Mishima M, 
Uematsu M, Shimazu T, Hori M, Abe H. Noninvasive evaluation of pulmonary 
hypertension by a pulsed Doppler technique. Circulation. 1983;68:302–309.  
8. Wang X, Tanus-Santos JE, Reiter CD, Dejam A, Shiva S, Smith RD, Hogg N, 
Gladwin MT. Biological activity of nitric oxide in the plasmatic compartment. Proc 
Natl Acad Sci USA. 2004;101:11477–11482.  
 
Page 58 of 72 AJRCCM Articles in Press. Published on 27-August-2014 as 10.1164/rccm.201405-0850OC 
 Copyright © 2014 by the American Thoracic Society 
Supplemental Tables 
Table E1. Hemodynamics and RHI after completing the transfusion 
 
 Baseline Time after Transfusion 
   
10 min 1 hour 4 hours 24 hours 
SAP, 
mmHg 
3d 125±3 120±3 119±3 121±4 126±4 
40d 123±4 121±4 124±4 122±6 128±5 
40d+NO 126±3 128±5 128±5 125±3 130±3 
DAP, 
mmHg 
3d 70±2 66±2 66±3 65±3 72±4 
40d 69±3 69±3 69±3 70±4 69±3 
40d+NO 70±3 67±2 72±3 69±4 73±2 
MAP, 
mmHg 
3d 88±2 84±2 84±2 84±3 90±3 
40d 87±3 86±3 88±3 88±4 89±3 
40+NO 89±2 87±3 90±3 88±3 92±2 
HR, bpm 
3d 70±3 63±3° 63±3° 69±4 67±3 
40d 68±4 61±3* 62±3* 67±3 67±4 
40d+NO 65±3 62±3 63±3 69±4 71±4 
LnRHI 
3d 0.74±0.9 
0.87±0.0
6 
0.87±0.0
7 
0.76±0.0
5 
0.74±0.06 
40d 
0.74±0.0
7 
0.90±0.0
6 
0.73±0.0
6 
0.76±0.0
5 
0.71±0.06 
40d+NO 
0.67±0.0
7 
0.78±0.0
6 
0.85±0.0
6 
0.83±0.0
6 
0.64±0.06 
Data mean±SEM. ° p<0.05 3d challenge values differ from before transfusion; * 
p<0.05 40d challenge values differ from before transfusion (two-way ANOVA for 
repeated measures with multiple comparisons). 
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Table E2. Renal and Hepatic markers 
 
 
Baselin
e 
Time after Transfusion 
   
10 min 1 hour 4 hours 
24 
hours 
Creatinine, 
mg/dl 
3d 
0.83±0.0
3 
0.84±0.3 
0.87±0.0
5 
0.86±0.04 0.87±0.4 
40d 
0.87±0.0
3 
0.86±0.3 
0.85±0.0
4 
0.89±0.04 
0.85±0.0
3 
40d+NO 
0.85±0.0
3 
0.83±0.0
4 
0.85±0.0
4 
0.91±0.03
# 
0.84±0.0
3 
BUN, mg/dl 
3d 13±1 12±1 12±1 12±1 13±1 
40d 13±1 13±1 12±1 13±1 13±1 
40d+NO 12±1 11±1 11±1 11±1 13±1 
NGAL, ng/ml 
3d 128±13 109±11 118±12 114±12 118±5 
40d 125±7 116±11 125±10 112±7 116±10 
40d+NO 109±11 108±13 122±23 98±10 92±10 
AST, U/l 
3d 23±3 23±3 23±3 25±6 26±5 
40d 27±5 26±4 26±4 27±5 24±3 
40d+NO 24±3 23±3 27±4 28±6 27±5 
ALT, U/l 
3d 25±4 25±5 25±5 26±6 29±6 
40d 24±5 23±5 24±5 24±5 22±3 
40d+NO 24±4 24±5 24±5 25±6 27±6 
Data are presented as mean±SEM. # p<0.05 value for 40d+NO differs from 
before transfusion (two-way ANOVA for repeated measures and multiple 
comparisons). BUN: blood urea nitrogen; NGAL: neutrophil gelatinase-
associated lipocalin; AST: aspartate aminotransferase; ALT: alanine 
aminotransferase. 
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   Baseline Time after Transfusion 
    
 
10 min 1 hour 4 hours 24 hours 
Plasma 
Nitrite, µM 
3d 
0.29  
(0.16-0.36) 
0.35  
(0.29-0.38) 
0.38  
(0.35-0.40) 
0.34  
(0.29-0.43) 
0.30  
(0.26-0.35) 
40d 
0.28 
(0.07-0.39) 
0.36  
(0.31-0.40) 
0.37  
(0.27-0.41) 
0.34  
(0.33-0.38) 
0.31  
(0.18-0.39) 
40d+NO 
0.17  
(0.06-0.40) 
0.34  
(0.30-0.44) 
0.36  
(0.30-0.42) 
0.41  
(0.36-0.47) 
0.38  
(0.34-0.42) 
Plasma 
Nitrate, µM 
3d 
21.52  
(15.82-
27.56) 
18.37  
(16.51-
21.61) 
16.92  
(14.30-
20.30) 
17.26  
(14.23-
23.19) 
17.02  
(14.81-
27.13) 
40d 
21.27 
(19.84-
27.00) 
18.01  
(15.93-
19.56) 
16.79  
(16.08-
18.29) 
17.85  
(14.21-
20.71) 
19.06  
(16.46-
22.48) 
40d+NO 
26.13  
(20.86-
30.32) 
55.55  
(22.75-
63.01) 
46.73  
(21.21-
56.44) 
41.43 
(19.83-
50.97) 
24.60  
(18.52-
40.39) 
Plasma 
RNNO, nM 
3d 
6.93  
(4.88-9.86) 
6.71  
(4.26-8.77) 
7.52  
(6.33-9.09) 
8.68  
(7.10-
11.65) 
9.39  
(7.38-
12.39) 
40d 
7.51 
(6.74-8.34) 
8.77  
(7.79-9.72) 
8.32  
(6.20-9.75) 
8.30  
(6.54-
10.16) 
7.41  
(5.73-
11.27) 
40d+NO 
7.87  
(6.45-9.61) 
9.09  
(7.20-
12.49) 
7.74  
(6.04-8.24) 
8.60  
(7.87-9.33) 
8.27  
(5.65-
10.85) 
Plasma 
RSNO, nM 
3d 
2.91  
(0.88-6.74) 
4.70  
(0.31-7.11) 
2.84  
(2.12-4.37) 
3.22  
(0.95-5.89) 
3.02  
(1.56-
10.55) 
40d 
2.00  
(1.67-4.79) 
1.28  
(0.73-2.71) 
2.85  
(1.68-6.31) 
2.08  
(0.70-4.39) 
4.04  
(2.06-7.81) 
40d+NO 
3.86  
(2.63-5.86) 
1.78 (0.95-
3.02) 
3.44 (0.86-
5.44) 
1.74 (0.87-
3.90) 
3.29 (1.43-
5.70) 
Plasma 
RXNO, nM 
3d 
11.33  
(7.75-15.09) 
10.80  
(8.92-
11.77) 
11.24  
(9.06-
11.96) 
10.93  
(9.95-
15.87) 
14.79  
(9.80-
18.93) 
40d 
10.26  
(8.71-12.14) 
10.19  
(9.26-
11.96) 
11.92  
(10.00-
12.96) 
11.12  
(8.97-
17.07) 
13.16  
(9.60-
15.21) 
40d+NO 
12.22  
(10.15-
16.32) 
11.07  
(9.49-
14.63) 
11.76  
(8.04-
12.98) 
10.98  
(9.84-
12.75) 
12.15  
(9.25-
13.44) 
Erythrocyte 
Nitrite, µM 
3d 
0.38  
(0.26-1.30) 
0.20 
(0.10-0.33) 
0.31  
(0.08-0.46) 
0.29  
(0.06-0.49) 
0.27  
(0.11-0.46) 
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40d 
0.50  
(0.39-0.81) 
0.26  
(0.19-0.42) 
0.37  
(0.16-0.47) 
0.26  
(0.17-0.39) 
0.34  
(0.20-0.49) 
40d+NO 
0.54  
(0.22-0.97) 
0.21  
(0.13-0.32) 
0.10  
(0.06-0.24) 
0.17  
(0.05-0.39) 
0.19  
(0.03-0.31) 
Erythrocyte 
Nitrate, µM 
3d 
27.59  
(24.06-
35.51) 
26.37  
(23.52-
30.71) 
26.31  
(19.28-
28.49) 
25.37  
(21.86-
32.76) 
22.85  
(19.04-
28.85) 
40d 
29.70  
(21.23-
32.98) 
20.81  
(20.14-
25.43) 
23.32  
(21.03-
27.77) 
21.40  
(19.47-
23.48) 
25.82  
(18.80-
29.50) 
40d+NO 
26.79  
(19.11-
43.25) 
51.30  
(21.61-
61.88) 
46.29  
(21.60-
54.52) 
40.50  
(19.55-
50.34) 
27.97  
(18.78-
43.08) 
Erythrocyte 
NO-heme, 
nM 
3d 
32.16 
(25.68-
41.24) 
26.92  
(25.29-
38.97) 
29.55  
(20.09-
35.59) 
30.33  
(25.13-
36.17) 
31.47  
(24.36-
43.67) 
40d 
26.52  
(21.40-
30.87) 
25.67  
(21.72-
29.21) 
24.71  
(13.90-
33.54) 
26.32  
(18.84-
30.34) 
27.80  
(18.18-
29.47) 
40d+NO 
31.63  
(28.69-
38.53) 
34.48  
(22.40-
50.34) 
35.56  
(23.99-
45.55) 
40.27  
(27.77-
53.09) 
38.52  
(25.54-
48.48) 
Erythrocyte 
RNNO, nM 
3d 
33.25  
(26.31-
59.62) 
38.60  
(29.87-
46.15) 
37.27  
(33.37-
45.93) 
44.45  
(32.95-
49.55) 
34.94  
(28.64-
44.00) 
40d 
36.03  
(29.48-
39.01) 
35.19  
(31.44-
37.65) 
33.67  
(31.37-
40.67) 
39.17  
(31.23-
45.51) 
39.05  
(29.13-
43.60) 
40d+NO 
38.11  
(33.89-
43.67) 
45.84  
(38.37-
48.46 
43.87  
(36.70-
55.16) 
52.96  
(42.71-
74.49) 
40.04  
(35.78-
59.86) 
Erythrocyte 
RSNO, nM 
3d 
12.26  
(8.19-17.91) 
18.20  
(11.61-
21.06) 
9.15  
(2.39-
22.48) 
12.87  
(7.14-
24.25) 
12.75  
(5.57-
26.75) 
40d 
11.43  
(6.20-19.18) 
8.45  
(6.28-
14.06) 
13.51  
(8.52-
22.97) 
10.67  
(6.22-
17.82) 
15.61  
(12.16-
19.05) 
40d+NO 
6.06  
(2.99-7.65) 
32.13  
(11.84-
38.16) 
8.75  
(2.53-
17.87) 
8.09  
(2.65-
16.18) 
15.26  
(6.29-
19.78) 
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Table E3. NO Metabolites 
Data are presented as median (IQR, interquartile range). 
  
Erythrocyte 
RXNO, nM 
3d 
46.81  
(41.91-
77.53) 
51.50  
(42.06-
65.61) 
48.44 
(43.66-
61.86) 
52.24 
(42.92-
68.79) 
52.81  
(43.28-
60.25) 
40d 
45.95  
(40.91-
61.03) 
45.53  
(43.64-
56.93) 
47.53  
(40.29-
56.96) 
53.54  
(42.64-
68.74) 
51.59  
(43.74-
57.28) 
40d+NO 
41.97  
(39.38-
53.94) 
73.10 
(51.71-
87.46) 
51.65  
(44.23-
65.75) 
62.08  
(47.02-
81.99) 
56.37  
(45.18-
81.04) 
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Supplemental Figure  
Figure E1. Study protocol 
 
The timeline of the day of the 3d, 40d and 40d+NO autologous RBC transfusion 
challenges is displayed. The timeline of the three days is identical, with the 
exception of inhaled NO that was administered only in the 40d+NO challenge. 
Volunteers were managed in the outpatient clinic of the Massachusetts General 
Hospital Blood Transfusion Service. Upon arrival for each of the 3 phases of the 
study (3d, 40d, and 40d+NO), volunteers reviewed the details of the protocol with 
a study staff member, the transfusion medicine nurse recorded vital signs, EKG, 
RHI and hemoglobin level, a physician reviewed data, performed a physical 
Page 64 of 72 AJRCCM Articles in Press. Published on 27-August-2014 as 10.1164/rccm.201405-0850OC 
 Copyright © 2014 by the American Thoracic Society 
exam and inserted a large bore IV in one of the antecubital vein (16G) for blood 
sampling and RBC infusion.  Blood samples were taken at baseline (before 
initiation of blood transfusion), at 10 minutes, 1 hour, 4 hours and 24 hours after 
the end of the RBC transfusion. Autologous leukoreduced RBC was infused over 
45 minutes. Transthoracic echocardiography was performed before each blood 
transfusion (TTE-Pre) and 15 minutes before completion of the blood transfusion 
(TTE-During).  A respiratory therapist was present during the administration of 
NO by face mask in the 40d+NO phase (online supplement, figure 2). NO was 
delivered at 80ppm at FIO2 between 21-23% for an hour before transfusion and 
for the entire time of the transfusion (total time of NO exposure = 1hour and 45 
minutes).  
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Figure E2. Changes of hemoglobin and white blood cell concentration 
(WBC) before and after transfusion with 3d, 40d and 40d+NO challenge 
blood 
 
The hematologic responses after transfusing 3d stored blood are shown in blue 
circles, 40d in red squares and 40d+NO in green triangles. (A) Hemoglobin 
concentration was increased similarly after transfusion of 3d, 40d and 40d+NO.  
°p<0.01 ∆ hemoglobin at 10 min and 24h measurements differs from baseline 
(=before transfusion) in 3d challenge (in blue).  
*p<0.01 ∆ hemoglobin at 10 min and 24h measurements differ compared to 
baseline (=before transfusion) in 40d challenge (in red).  
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#p<0.01 ∆ hemoglobin at 10 min and 24h measurements differ as compared to 
baseline (=before transfusion) in 40d+NO challenge (in green).  
 
Figure (B) White blood cell concentration increased  at 4 h after transfusion of 
40d stored blood (*p<0.01 ∆ white blood count differs at 4h measurement 
compared to baseline (=before transfusion) in 40d challenge (in red)).  
 
In Figure (A) and (B) the data are presented as mean ± SEM. A Two-way 
ANOVA for repeated measures with a post-hoc Bonferroni correction was used 
to test for significant differences. 
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Figure E3. Measurements of serum iron and indirect bilirubin before and 
after challenge  with 3d, 40d and 40d+NO blood 
 
 
(A) Serum iron levels (µg/dl) are increased at 1h, and peak at 4h after transfusion 
with 40d stored blood as compared to baseline (40d and 40d+NO). # p<0.001 
plasma iron at 1h and 4h measurements differ as compared to baseline in 
40d+NO challenge ( green). * p<0.001 plasma cell-free Hb at 1h and 4h 
measurements differ as compared to baseline in 40d challenge ( red).  
(B) Indirect bilirubin (unconjugated) was elevated at 1 and 4h.  
# p<0.001 indirect bilirubin at 1h and 4h measurements differ when compared to 
baseline (=before transfusion) in 40d+NO challenge (green). * p<0.001 indirect 
bilirubin at 1h and 4h measurements differ as compared to baseline in 40d 
challenge (red).  
All data are presented as mean ± SEM.  A Two-way ANOVA for repeated 
measures with a post-hoc Bonferroni correction was used to test significance. 
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Figure E4. In vivo Nitric Oxide metabolite concentrations before and after 
transfusions with 3d, 40d and 40d+NO blood 
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 (A) Plasma and (B) erythrocytic nitrate (µM) concentration are increased only 
after breathing NO at 80ppm for 1h 45min. In figure (A) #p<0.01 plasma nitrate at 
1h, 4h and 24h measurements differ as compared to baseline in 40d+NO 
challenge (in green). Figure (B) #p<0.01 erythrocytic nitrate at 10 min 
measurements differ from baseline in 40d+NO challenge (in green)). (C) Plasma 
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nitrite (µM) is slightly increased after transfusion of 40d+NO (#p<0.01 plasma 
nitrite at 10 min, 1h, 4h and 24h measurements differ from baseline  in 40d+NO 
challenge (in green)), (D) while Nitrite levels are decreased in the erythrocytes 
(#p<0.01 erythrocytic nitrite at 10 min, 1h, 4h and 24h measurements differ as 
compared to baseline  in 40d+NO challenge (green). °p<0.01 erythrocytic nitrite 
at 10 min, 1h, 4h and 24h measurements differ as compared to baseline in 3d 
challenge (blue)). (E) and (F), RxNO is the concentration of N-nitrosamines and 
S-nitrosothiols. An acute increase occurs immediately after NO inhalation in 
erythrocytes (#p<0.01 erythrocytic RxNO at 10 min measurements compared to 
baseline in 40d+NO challenge (in green)). In figures (A), (B), (C), (D), (E) and (F) 
all data are presented as mean ± SEM. A two-way ANOVA for repeated 
measures with post-hoc Bonferroni correction was used to test for significance. 
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Figure E5. Nitric Oxide delivery system 
 
The circuit consisted of standard oxygen tubing connected via  15 x 4.5 mm and 
a 15 x 22 mm adaptors to a tee piece and 2 liter reservoir bag placed at the inlet 
of the injector module, 5 feet of standard corrugated tubing was attached to the 
outlet of the injector module, a sample tee was added to continuously monitor 
inspired gas concentrations, followed by 6 additional inches of standard 
corrugated tubing, and a one way valve tee piece connected to a Respironics M 
Performatrak SE tight fitting facemask to prevent re-breathing of expired gas. A 
room air concentrator was set to deliver 40 Liters/minute providing the bulk of the 
inspiratory gas flow into the circuit and reservoir bag. Additionally, 1 liter/minute 
of oxygen was added with a 15 x 22 mm side arm adaptor to maintain an inspired 
oxygen concentration of 21 to 23%. Nitric oxide was delivered at 80ppm using 
the Ikaria INOvent Delivery System (Ikaria, Hampton, NJ).  
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